BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 32105673)

  • 1. Medulloblastoma: Molecular understanding, treatment evolution, and new developments.
    Liu X; Ding C; Tan W; Zhang A
    Pharmacol Ther; 2020 Jun; 210():107516. PubMed ID: 32105673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling pathway and molecular subgroups of medulloblastoma.
    Li KK; Lau KM; Ng HK
    Int J Clin Exp Pathol; 2013; 6(7):1211-22. PubMed ID: 23826403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Approaches in Targeted Therapy for Medulloblastoma in Children.
    Maier H; Dalianis T; Kostopoulou ON
    Anticancer Res; 2021 Apr; 41(4):1715-1726. PubMed ID: 33813375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rationale for targeted therapies in medulloblastoma.
    MacDonald TJ; Aguilera D; Castellino RC
    Neuro Oncol; 2014 Jan; 16(1):9-20. PubMed ID: 24305711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li Y; Song Q; Day BW
    Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular subgroups of adult medulloblastoma: a long-term single-institution study.
    Zhao F; Ohgaki H; Xu L; Giangaspero F; Li C; Li P; Yang Z; Wang B; Wang X; Wang Z; Ai L; Zhang J; Luo L; Liu P
    Neuro Oncol; 2016 Jul; 18(7):982-90. PubMed ID: 27106407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
    Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
    PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medulloblastoma genomics in the modern molecular era.
    Kumar R; Liu APY; Northcott PA
    Brain Pathol; 2020 May; 30(3):679-690. PubMed ID: 31799776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Classification of Medulloblastoma.
    Kijima N; Kanemura Y
    Neurol Med Chir (Tokyo); 2016 Nov; 56(11):687-697. PubMed ID: 27238212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medulloblastoma cancer stem cells: molecular signatures and therapeutic targets.
    Bahmad HF; Poppiti RJ
    J Clin Pathol; 2020 May; 73(5):243-249. PubMed ID: 32034059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BMI1 is a therapeutic target in recurrent medulloblastoma.
    Bakhshinyan D; Venugopal C; Adile AA; Garg N; Manoranjan B; Hallett R; Wang X; Mahendram S; Vora P; Vijayakumar T; Subapanditha M; Singh M; Kameda-Smith MM; Qazi M; McFarlane N; Mann A; Ajani OA; Yarascavitch B; Ramaswamy V; Farooq H; Morrissy S; Cao L; Sydorenko N; Baiazitov R; Du W; Sheedy J; Weetall M; Moon YC; Lee CS; Kwiecien JM; Delaney KH; Doble B; Cho YJ; Mitra S; Kaplan D; Taylor MD; Davis TW; Singh SK
    Oncogene; 2019 Mar; 38(10):1702-1716. PubMed ID: 30348991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
    Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
    Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
    Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
    Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
    Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK
    BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.
    Sursal T; Ronecker JS; Dicpinigaitis AJ; Mohan AL; Tobias ME; Gandhi CD; Jhanwar-Uniyal M
    Anticancer Res; 2022 May; 42(5):2225-2239. PubMed ID: 35489737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma.
    Andrade AF; Borges KS; Suazo VK; Geron L; Corrêa CA; Castro-Gamero AM; de Vasconcelos EJ; de Oliveira RS; Neder L; Yunes JA; Dos Santos Aguiar S; Scrideli CA; Tone LG
    Invest New Drugs; 2017 Feb; 35(1):26-36. PubMed ID: 27785591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosomal microRNAs induce tumor-associated macrophages via PPARγ during tumor progression in SHH medulloblastoma.
    Zhu L; Yang Y; Li H; Xu L; You H; Liu Y; Liu Z; Liu X; Zheng D; Bie J; Li J; Song C; Yang B; Luo J; Chang Q
    Cancer Lett; 2022 Jun; 535():215630. PubMed ID: 35304257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SHH inhibitors for the treatment of medulloblastoma.
    Samkari A; White J; Packer R
    Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced hydroxymethylation characterizes medulloblastoma while TET and IDH genes are differentially expressed within molecular subgroups.
    Bezerra Salomão K; Cruzeiro GAV; Bonfim-Silva R; Geron L; Ramalho F; Pinto Saggioro F; Serafini LN; Antunes Moreno D; de Paula Queiroz RG; Dos Santos Aguiar S; Cardinalli I; Yunes JA; Brandalise SR; Brassesco MS; Scrideli CA; Gonzaga Tone L
    J Neurooncol; 2018 Aug; 139(1):33-42. PubMed ID: 29582271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.